Skip to main content
SpringerLink
Log in

Pharmacological Management of Narcolepsy and Cataplexy in Pediatric Patients

  • Review Article
  • Published:
Pediatric Drugs Aims and scope Submit manuscript

Abstract

Narcolepsy is a neurological disorder frequently occurring from childhood and persisting through adolescence and adulthood. Individuals suffering from narcolepsy exhibit excessive daytime somnolence, sleep attacks, cataplexy, dysomnia, metabolic perturbations including weight gain, and problems in social interaction and academic performance. The prevalence of narcolepsy in childhood is not known but can be estimated from adult studies to be greater than 20–60 per 100,000 in Western countries. The 2009 (A) H1N1 vaccination campaign led to an increase of narcoleptic cases both in children and in adults, supporting the autoimmune hypothesis of the disease. This article focuses on the epidemiology, etiology, and particularities of treatment in pediatric narcolepsy and details the effects of the drugs used to treat this condition, including recent trends in the field. Future therapeutic directions are also discussed. At present, medications used to treat children or adolescents have shown efficacy mostly based on clinical experience, given the lack of level 1 evidence-based studies in the pediatric population. Therefore, most compounds used in adult narcolepsy to target clinical symptoms such as wake-promoting or anticataplectic agents are prescribed off-label in pediatric patients. Published research shows the benefit of drug therapy for narcoleptic children, but these must be dispensed with caution in the absence of well conducted clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. American Academy of Sleep Medicine. The international classification of sleep disorders, revised: diagnostic and coding manual. 3rd ed. Rochester: American Academy of Sleep Medicine; 2014.

    Google Scholar 

  2. Roth T, Dauvilliers Y, Mignot E, Montplaisir J, Paul J, Swick T, et al. Disrupted nighttime sleep in narcolepsy. J Clin Sleep Med. 2013;9(9):955–65.

    PubMed  PubMed Central  Google Scholar 

  3. Silber MH, Krahn LE, Olson EJ, Pankratz VS. The epidemiology of narcolepsy in Olmsted County, Minnesota: a population-based study. Sleep. 2002;25(2):197–202.

    PubMed  Google Scholar 

  4. Longstreth WT Jr, Koepsell TD, Ton TG, Hendrickson AF, van Belle G. The epidemiology of narcolepsy. Sleep. 2007;30(1):13–26.

    PubMed  Google Scholar 

  5. Faraco J, Lin L, Kornum BR, Kenny EE, Trynka G, Einen M, et al. ImmunoChip study implicates antigen presentation to T cells in narcolepsy. PLoS Genet. 2013;9(2):e1003270.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  6. Nishino S, Ripley B, Overeem S, Nevsimalova S, Lammers GJ, Vankova J, et al. Low cerebrospinal fluid hypocretin (Orexin) and altered energy homeostasis in human narcolepsy. Ann Neurol. 2001;50(3):381–8.

    Article  PubMed  CAS  Google Scholar 

  7. De la Herrán-Arita AK et al. CD4+ T cell autoimmunity to hypocretin/orexin and cross-reactivity to a 2009 H1N1 influenza a epitope in narcolepsy. Sci Transl Med. 2013;5:216ra176. doi:10.1126/scitranslmed.3007762

  8. Bonnavion P, de Lecea L. Hypocretins in the control of sleep and wakefulness. Curr Neurol Neurosci Rep. 2010;10(3):174–9.

    Article  PubMed  CAS  Google Scholar 

  9. Baimel C, Bartlett SE, Chiou LC, Lawrence AJ, Muschamp JW, Patkar O, et al. Orexin/hypocretin role in reward: implications for opioid and other addictions. Br J Pharmacol. Epub 15 Feb 2014.

  10. Dauvilliers Y, Montplaisir J, Molinari N, Carlander B, Ondze B, Besset A, et al. Age at onset of narcolepsy in two large populations of patients in France and Quebec. Neurology. 2001;57(11):2029–33.

    Article  PubMed  CAS  Google Scholar 

  11. Okun ML, Lin L, Pelin Z, Hong S, Mignot E. Clinical aspects of narcolepsy–cataplexy across ethnic groups. Sleep. 2002;25(1):27–35.

    PubMed  Google Scholar 

  12. Singh AK, Mahlios J, Mignot E. Genetic association, seasonal infections and autoimmune basis of narcolepsy. J Autoimmun. 2013;43:26–31.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  13. De la Herran-Arita AK, Garcia-Garcia F. Narcolepsy as an immune-mediated disease. Sleep Disord. 2014;2014:792687.

    PubMed  PubMed Central  Google Scholar 

  14. Pizza F, Franceschini C, Peltola H, Vandi S, Finotti E, Ingravallo F, et al. Clinical and polysomnographic course of childhood narcolepsy with cataplexy. Brain. 2013;136(Pt 12):3787–95.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Poli F, Pizza F, Mignot E, Ferri R, Pagotto U, Taheri S, et al. High prevalence of precocious puberty and obesity in childhood narcolepsy with cataplexy. Sleep. 2013;36(2):175–81.

    PubMed  PubMed Central  Google Scholar 

  16. Plazzi G, Parmeggiani A, Mignot E, Lin L, Scano MC, Posar A, et al. Narcolepsy–cataplexy associated with precocious puberty. Neurology. 2006;66(10):1577–9.

    Article  PubMed  CAS  Google Scholar 

  17. Inocente CO, Lavault S, Lecendreux M, Dauvilliers Y, Reimao R, Gustin MP, et al. Impact of obesity in children with narcolepsy. CNS Neurosci Ther. 2013;19(7):521–8.

    Article  PubMed  Google Scholar 

  18. Kotagal S, Krahn LE, Slocumb N. A putative link between childhood narcolepsy and obesity. Sleep Med. 2004;5(2):147–50.

    Article  PubMed  Google Scholar 

  19. Perriol MP, Cartigny M, Lamblin MD, Poirot I, Weill J, Derambure P, et al. Childhood-onset narcolepsy, obesity and puberty in four consecutive children: a close temporal link. J Pediatr Endocrinol Metab. 2010;23(3):257–65.

    Article  PubMed  Google Scholar 

  20. Aran A, Einen M, Lin L, Plazzi G, Nishino S, Mignot E. Clinical and therapeutic aspects of childhood narcolepsy–cataplexy: a retrospective study of 51 children. Sleep. 2010;33(11):1457–64.

    PubMed  PubMed Central  Google Scholar 

  21. Posar A, Pizza F, Parmeggiani A, Plazzi G. Neuropsychological findings in childhood narcolepsy. J Child Neurol. Epub 2013 Nov 28.

  22. Huang YS, Guilleminault C, Chen CH, Lai PC, Hwang FM. Narcolepsy–cataplexy and schizophrenia in adolescents. Sleep Med. 2014;15(1):15–22.

    Article  PubMed  Google Scholar 

  23. Sonka K, Kemlink D, Buskova J, Pretl M, Srutkova Z, Maurovich Horvat E, et al. Obesity accompanies narcolepsy with cataplexy but not narcolepsy without cataplexy. Neuro Endocrinol Lett. 2010;31(5):631–4.

    PubMed  Google Scholar 

  24. Stores G, Montgomery P, Wiggs L. The psychosocial problems of children with narcolepsy and those with excessive daytime sleepiness of uncertain origin. Pediatrics. 2006;118(4):e1116–23.

    Article  PubMed  Google Scholar 

  25. Dorris L, Zuberi SM, Scott N, Moffat C, McArthur I. Psychosocial and intellectual functioning in childhood narcolepsy. Dev Neurorehabil. 2008;11(3):187–94.

    Article  PubMed  Google Scholar 

  26. Peraita-Adrados R, Garcia-Penas JJ, Ruiz-Falco L, Gutierrez-Solana L, Lopez-Esteban P, Vicario JL, et al. Clinical, polysomnographic and laboratory characteristics of narcolepsy–cataplexy in a sample of children and adolescents. Sleep Med. 2011;12(1):24–7.

    Article  PubMed  Google Scholar 

  27. Inocente CO, Gustin MP, Lavault S, Guignard-Perret A, Raoux A, Christol N, et al. Depressive feelings in children with narcolepsy. Sleep Med. 2014;15(3):309–14.

    Article  PubMed  Google Scholar 

  28. Ohayon MM. Narcolepsy is complicated by high medical and psychiatric comorbidities: a comparison with the general population. Sleep Med. 2013;14(6):488–92.

    Article  PubMed  Google Scholar 

  29. Thorpy MJ, Krieger AC. Delayed diagnosis of narcolepsy: characterization and impact. Sleep Med. 2014;15:502–7.

    Article  PubMed  Google Scholar 

  30. Jennum P, Knudsen S, Kjellberg J. The economic consequences of narcolepsy. J Clin Sleep Med. 2009;5(3):240–5.

    PubMed  PubMed Central  Google Scholar 

  31. Inocente CO, Gustin MP, Lavault S, Guignard-Perret A, Raoux A, Christol N, et al. Quality of life in children with narcolepsy. CNS Neurosci Ther. 2014. [Epub ahead of print].

  32. Lecendreux M. Quality of life in children with narcolepsy and cataplexy. Sleep Med Clin. 2014;9:211–7

    Article  Google Scholar 

  33. Dauvilliers Y, Carlander B, Rivier F, Touchon J, Tafti M. Successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset. Ann Neurol. 2004;56(6):905–8.

    Article  PubMed  CAS  Google Scholar 

  34. Plazzi G, Poli F, Franceschini C, Parmeggiani A, Pirazzoli P, Bernardi F, et al. Intravenous high-dose immunoglobulin treatment in recent onset childhood narcolepsy with cataplexy. J Neurol. 2008;255(10):1549–54.

    Article  PubMed  Google Scholar 

  35. Vitiello B. Understanding the risk of using medications for attention deficit hyperactivity disorder with respect to physical growth and cardiovascular function. Child Adolesc Psychiatr Clin N Am. 2008;17(2):459–74.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Rugino T. A review of modafinil film-coated tablets for attention-deficit/hyperactivity disorder in children and adolescents. Neuropsychiatr Dis Treat. 2007;3(3):293–301.

    PubMed  CAS  PubMed Central  Google Scholar 

  37. Provigil® [modafinil] tablets US prescribing information. Frazer: Cephalon, Inc.; 2010.

  38. Nuvigil® [armodafinil] tablets US prescribing information. Frazer: Cephalon, Inc.; 2010.

  39. Geller B, Reising D, Leonard HL, Riddle MA, Walsh BT. Critical review of tricyclic antidepressant use in children and adolescents. J Am Acad Child Adolesc Psychiatry. 1999;38(5):513–6.

    Article  PubMed  CAS  Google Scholar 

  40. Billiard M, Bassetti C, Dauvilliers Y, Dolenc-Groselj L, Lammers GJ, Mayer G, et al. EFNS guidelines on management of narcolepsy. Eur J Neurol. 2006;13(10):1035–48.

    Article  PubMed  CAS  Google Scholar 

  41. Morgenthaler TI, Kapur VK, Brown T, Swick TJ, Alessi C, Aurora RN, et al. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. Sleep. 2007;30(12):1705–11.

    PubMed  PubMed Central  Google Scholar 

  42. Guilleminault C, Fromherz S. Narcolepsy: diagnosis and management. In: Kryger MH, Roth T, Dement WC, editors. Principles and practice of sleep medicine. 5th ed. St. Louis: Elsevier; 2011.

    Google Scholar 

  43. Mignot EJ. A practical guide to the therapy of narcolepsy and hypersomnia syndromes. Neurotherapeutics. 2012;9(4):739–52.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Lecendreux M. Pediatric narcolepsy: clinical and therapeutical approaches. Handb Clin Neurol. 2013;112:839–45.

    Article  Google Scholar 

  45. Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy: US Modafinil in Narcolepsy Multicenter Study Group. Neurology. 2000;54(5):1166–75.

  46. Harsh JR, Hayduk R, Rosenberg R, Wesnes KA, Walsh JK, Arora S, et al. The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy. Curr Med Res Opin. 2006;22(4):761–74.

    Article  PubMed  CAS  Google Scholar 

  47. Black J, Houghton WC. Sodium oxybate improves excessive daytime sleepiness in narcolepsy. Sleep. 2006;29(7):939–46.

    PubMed  Google Scholar 

  48. Ivanenko A, Tauman R, Gozal D. Modafinil in the treatment of excessive daytime sleepiness in children. Sleep Med. 2003;4(6):579–82.

    Article  PubMed  Google Scholar 

  49. Owens J, Bogan R, Lankford A, Sheldon S. Modafinil is well tolerated in children and adolescents with excessive sleepiness and obstructive sleep apnea: a 6- week double blind study [abstract]. Sleep. 2007;30(Suppl):A88–9.

    Google Scholar 

  50. Lecendreux M, Bruni O, Franco P, Gringras P, Konofal E, Nevsimalova S, et al. Clinical experience suggests that modafinil is an effective and safe treatment for paediatric narcolepsy. J Sleep Res. 2012;21(4):481–3.

    Article  PubMed  Google Scholar 

  51. Xyrem US, Multicenter Study Group. Sodium oxybate demonstrates long-term efficacy for the treatment of cataplexy in patients with narcolepsy. Sleep Med. 2004;5(2):119–23.

    Article  Google Scholar 

  52. Xyrem International Study Group. Further evidence supporting the use of sodium oxybate for the treatment of cataplexy: a double-blind, placebo-controlled study in 228 patients. Sleep Med. 2005;6(5):415–21.

    Article  Google Scholar 

  53. Murali H, Kotagal S. Off-label treatment of severe childhood narcolepsy–cataplexy with sodium oxybate. Sleep. 2006;29(8):1025–9.

    PubMed  Google Scholar 

  54. Lecendreux M, Poli F, Oudiette D, Benazzouz F, Donjacour CE, Franceschini C, et al. Tolerance and efficacy of sodium oxybate in childhood narcolepsy with cataplexy: a retrospective study. Sleep. 2012;35(5):709–11.

    PubMed  PubMed Central  Google Scholar 

  55. Bogan RK, Roth T, Schwartz J, Miloslavsky M, Scharf M. Time to response with sodium oxybate for the treatment of excessive daytime sleepiness (EDS) and cataplexy in patients with narcolepsy [APSS 2014 Abstract 0667]. Sleep. 2014;37(suppl):A233.

    Google Scholar 

  56. Modestino EJ, Winchester J. A retrospective survey of childhood ADHD symptomatology among adult narcoleptics. J Atten Disord. 2013;17(7):574–82.

    Article  PubMed  Google Scholar 

  57. Edgar DM, Seidel WF. Modafinil induces wakefulness without intensifying motor activity or subsequent rebound hypersomnolence in the rat. J Pharmacol Exp Ther. 1997;283(2):757–69.

    PubMed  CAS  Google Scholar 

  58. Gruner JA, Marcy VR, Lin YG, Bozyczko-Coyne D, Marino MJ, Gasior M. The roles of dopamine transport inhibition and dopamine release facilitation in wake enhancement and rebound hypersomnolence induced by dopaminergic agents. Sleep. 2009;32(11):1425–38.

    PubMed  PubMed Central  Google Scholar 

  59. Pennick M. Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine. Neuropsychiatr Dis Treat. 2010;6:317–27.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  60. Wigal SB, Kollins SH, Childress AC, Squires L. A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder. Child Adolesc Psychiatry Ment Health. 2009;3(1):17.

    Article  PubMed  PubMed Central  Google Scholar 

  61. Wigal T, Brams M, Gasior M, Gao J, Squires L, Giblin J. Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design. Behav Brain Funct. 2010;6:34.

    Article  PubMed  PubMed Central  Google Scholar 

  62. Biederman J, Krishnan S, Zhang Y, McGough JJ, Findling RL. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. Clin Ther. 2007;29(3):450–63.

    Article  PubMed  CAS  Google Scholar 

  63. Findling RL, Childress AC, Cutler AJ, Gasior M, Hamdani M, Ferreira-Cornwell MC, et al. Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2011;50(4):395–405.

    Article  PubMed  Google Scholar 

  64. Adler LA, Goodman DW, Kollins SH, Weisler RH, Krishnan S, Zhang Y, et al. Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2008;69(9):1364–73.

    Article  PubMed  CAS  Google Scholar 

  65. Coghill D, Banaschewski T, Lecendreux M, Soutullo C, Johnson M, Zuddas A, et al. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder. Eur Neuropsychopharmacol. 2013;23(10):1208–18.

    Article  PubMed  CAS  Google Scholar 

  66. Donjacour CE, Aziz NA, Frolich M, Roelfsema F, Overeem S, Lammers GJ, et al. Sodium oxybate increases prolactin secretion in narcolepsy patients and healthy controls. Eur J Endocrinol. 2011;164(3):363–70.

    Article  PubMed  CAS  Google Scholar 

  67. Donjacour CE, Aziz NA, Roelfsema F, Frolich M, Overeem S, Lammers GJ, et al. Effect of sodium oxybate on growth hormone secretion in narcolepsy patients and healthy controls. Am J Physiol Endocrinol Metab. 2011;300(6):E1069–75.

    Article  PubMed  CAS  Google Scholar 

  68. Donjacour CEHM, Lammers GJ, Lecendreux M. Endocrine aspects of pharmacotherapy in narcolepsy. J Sleep Res. 2012;21(Suppl s1):45.

    Google Scholar 

  69. Alvarez B, Dahlitz M, Grimshaw J, Parkes JD. Mazindol in long-term treatment of narcolepsy. Lancet. 1991;337(8752):1293–4.

    Article  PubMed  CAS  Google Scholar 

  70. Nittur N, Konofal E, Dauvilliers Y, Franco P, Leu-Semenescu S, Cock VC, et al. Mazindol in narcolepsy and idiopathic and symptomatic hypersomnia refractory to stimulants: a long-term chart review. Sleep Med. 2013;14(1):30–6.

    Article  PubMed  Google Scholar 

  71. Moller LR, Ostergaard JR. Treatment with venlafaxine in six cases of children with narcolepsy and with cataplexy and hypnagogic hallucinations. J Child Adolesc Psychopharmacol. 2009;19(2):197–201.

    Article  PubMed  Google Scholar 

  72. Ratkiewicz M, Splaingard M. Treatment of cataplexy in a three-year-old using venlafaxine. J Clin Sleep Med. 2013;9(12):1341–2.

    PubMed  PubMed Central  Google Scholar 

  73. Lecendreux M, Maret S, Bassetti C, Mouren MC, Tafti M. Clinical efficacy of high-dose intravenous immunoglobulins near the onset of narcolepsy in a 10-year-old boy. J Sleep Res. 2003;12(4):347–8.

    Article  PubMed  Google Scholar 

  74. Knudsen S, Mikkelsen JD, Bang B, Gammeltoft S, Jennum PJ. Intravenous immunoglobulin treatment and screening for hypocretin neuron-specific autoantibodies in recent onset childhood narcolepsy with cataplexy. Neuropediatrics. 2010;41(5):217–22.

    Article  PubMed  CAS  Google Scholar 

  75. Fronczek R, Verschuuren J, Lammers GJ. Response to intravenous immunoglobulins and placebo in a patient with narcolepsy with cataplexy. J Neurol. 2007;254(11):1607–8.

    Article  PubMed  Google Scholar 

  76. Valko PO, Khatami R, Baumann CR, Bassetti CL. No persistent effect of intravenous immunoglobulins in patients with narcolepsy with cataplexy. J Neurol. 2008;255(12):1900–3.

    Article  PubMed  Google Scholar 

  77. Dauvilliers Y, Abril B, Mas E, Michel F, Tafti M. Normalization of hypocretin-1 in narcolepsy after intravenous immunoglobulin treatment. Neurology. 2009;73(16):1333–4.

    Article  PubMed  CAS  Google Scholar 

  78. Knudsen S, Biering-Sorensen B, Kornum BR, Petersen ER, Ibsen JD, Gammeltoft S, et al. Early IVIg treatment has no effect on post-H1N1 narcolepsy phenotype or hypocretin deficiency. Neurology. 2012;79(1):102–3.

    Article  PubMed  Google Scholar 

  79. Ligneau X, Perrin D, Landais L, Camelin JC, Calmels TP, Berrebi-Bertrand I, et al. BF2.649 [1-{3-[3-(4-Chlorophenyl)propoxy]propyl}piperidine, hydrochloride], a nonimidazole inverse agonist/antagonist at the human histamine H3 receptor: preclinical pharmacology. J Pharmacol Exp Ther. 2007;320(1):365–75.

    Article  PubMed  CAS  Google Scholar 

  80. Parmentier R, Anaclet C, Guhennec C, Brousseau E, Bricout D, Giboulot T, et al. The brain H3-receptor as a novel therapeutic target for vigilance and sleep-wake disorders. Biochem Pharmacol. 2007;73(8):1157–71.

    Article  PubMed  CAS  Google Scholar 

  81. Schwartz JC. The histamine H3 receptor: from discovery to clinical trials with pitolisant. Br J Pharmacol. 2011;163(4):713–21.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  82. Lin JS, Dauvilliers Y, Arnulf I, Bastuji H, Anaclet C, Parmentier R, et al. An inverse agonist of the histamine H(3) receptor improves wakefulness in narcolepsy: studies in orexin−/− mice and patients. Neurobiol Dis. 2008;30(1):74–83.

    Article  PubMed  Google Scholar 

  83. Chemelli RM, Willie JT, Sinton CM, Elmquist JK, Scammell T, Lee C, et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell. 1999;98(4):437–51.

    Article  PubMed  CAS  Google Scholar 

  84. Dauvilliers Y, Bassetti C, Lammers GJ, Arnulf I, Mayer G, Rodenbeck A, et al. Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial. Lancet Neurol. 2013;12(11):1068–75.

    Article  PubMed  CAS  Google Scholar 

  85. Inocente C, Arnulf I, Bastuji H, Thibault-Stoll A, Raoux A, Reimao R, et al. Pitolisant, an inverse agonist of the histamine H3 receptor: an alternative stimulant for narcolepsy–cataplexy in teenagers with refractory sleepiness. Clin Neuropharmacol. 2012;35(2):55–60.

    Article  PubMed  CAS  Google Scholar 

  86. Baier PC, Hallschmid M, Seeck-Hirschner M, Weinhold SL, Burkert S, Diessner N, et al. Effects of intranasal hypocretin-1 (orexin A) on sleep in narcolepsy with cataplexy. Sleep Med. 2011;12(10):941–6.

    Article  PubMed  CAS  Google Scholar 

  87. Weinhold SL, Seeck-Hirschner M, Nowak A, Hallschmid M, Goder R, Baier PC. The effect of intranasal orexin-A (hypocretin-1) on sleep, wakefulness and attention in narcolepsy with cataplexy. Behav Brain Res. 2014;262:8–13.

    Article  PubMed  CAS  Google Scholar 

Download references

Conflicts of interest

Michel Lecendreux is a consultant for UCB Pharma, Jazz, Bioprojet, and Shire. He has no shares and no conflicts of interests with Cephalon, Teva, or Midy. No sources of funding were used to assist with the preparation of this review.

Author information

Authors and Affiliations

  1. Pediatric Sleep Center and National Reference Center for Orphan Diseases, Narcolepsy, Idiopathic Hypersomnia and Kleine–Levin Syndrome, Robert Debre University Hospital, 48 Boulevard Serurier, 75019, Paris, France

    Michel Lecendreux

Authors
  1. Michel Lecendreux
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michel Lecendreux.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lecendreux, M. Pharmacological Management of Narcolepsy and Cataplexy in Pediatric Patients. Pediatr Drugs 16, 363–372 (2014). https://doi.org/10.1007/s40272-014-0083-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40272-014-0083-3

Keywords

Search

Navigation